A new trading day began on Monday, with Lexaria Bioscience Corp (NASDAQ: LEXX) stock price up 32.44% from the previous day of trading, before settling in for the closing price of $0.79. LEXX’s price has ranged from $0.77 to $4.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 21.61%. Meanwhile, its annual earnings per share averaged -47.87%. With a float of $17.96 million, this company’s outstanding shares have now reached $19.46 million.
Let’s determine the extent of company efficiency that accounts for 7 employees.
Lexaria Bioscience Corp (LEXX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lexaria Bioscience Corp is 8.19%, while institutional ownership is 11.74%. The most recent insider transaction that took place on Jul 29 ’25, was worth 14,375. In this transaction Director of this company bought 15,600 shares at a rate of $0.92, taking the stock ownership to the 270,012 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 11,900 for $0.91, making the entire transaction worth $10,866. This insider now owns 281,912 shares in total.
Lexaria Bioscience Corp (LEXX) Recent Fiscal highlights
In its latest quarterly report, released on 8/31/2024, the company reported earnings of -0.15 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -47.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.84% during the next five years compared to 21.61% growth over the previous five years of trading.
Lexaria Bioscience Corp (NASDAQ: LEXX) Trading Performance Indicators
Here are Lexaria Bioscience Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Lexaria Bioscience Corp (LEXX)
Looking closely at Lexaria Bioscience Corp (NASDAQ: LEXX), its last 5-days average volume was 0.29 million, which is a jump from its year-to-date volume of 0.14 million. As of the previous 9 days, the stock’s Stochastic %D was 38.65%.
During the past 100 days, Lexaria Bioscience Corp’s (LEXX) raw stochastic average was set at 29.70%, which indicates a significant decrease from 90.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0682 in the past 14 days, which was lower than the 0.0778 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8911, while its 200-day Moving Average is $1.4731. However, in the short run, Lexaria Bioscience Corp’s stock first resistance to watch stands at $1.1520. Second resistance stands at $1.2540. The third major resistance level sits at $1.4280. If the price goes on to break the first support level at $0.8760, it is likely to go to the next support level at $0.7020. Now, if the price goes above the second support level, the third support stands at $0.6000.
Lexaria Bioscience Corp (NASDAQ: LEXX) Key Stats
With a market capitalization of 20.54 million, the company has a total of 19,559K Shares Outstanding. Currently, annual sales are 460 K while annual income is -5,800 K. The company’s previous quarter sales were 170 K while its latest quarter income was -3,790 K.
